About BOAN BIOTECH Company

Shandong Boan Biotechnology Co., Ltd. (“Boan Biology” or “the Company”, together with its subsidiaries collectively referred to as the “Group”) was established in 2013. It is a comprehensive biopharmaceutical company specializing in R&D, production and marketing of biological products, focusing on treatment fields such as tumors, autoimmune diseases, ophthalmology and metabolic diseases. The company carries out drug discovery activities around multiple platforms: whole-human antibody-transgenic mice and bacteriophage display technology platforms, dual-specific T-cellEngager technology platforms, ADC technology platforms, and cell therapy platforms. Boan Biotech's business covers the entire industry chain, covering antibody discovery, cell line development, upstream and downstream process development, analytical and bioanalytical method development, technology transfer, non-clinical research, clinical research, regulations and registration, and commercial-scale production. In the field of cell therapy, Boan Biotech focuses on a new generation of enhanced and controlled T cell therapy technology to develop safer, more effective, and affordable treatments for patients. Boan Biotech's product portfolio includes three commercial products, and its product pipeline includes a variety of innovative biopharmaceuticals with international intellectual property protection and several candidate biosimilar drugs. In addition to the People's Republic of China (“China”), the Company is also developing biological products in overseas markets such as the United States of America (“US”), the European Union (“EU”), and Japan. With its differentiated product portfolio and mature commercialization capabilities, Boan Biotech's business covers the entire “R&D-production-commercialization” industry chain, laying a solid foundation for future long-term, high-quality growth.